Sana Biotechnology, Inc. (SANA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sana Biotechnology, Inc. (SANA) Healthcare & Pipeline Overview

Sana Biotechnology, Inc. pioneers engineered cell therapies, developing ex vivo and in vivo platforms for oncology, diabetes, and neurological disorders. With a focus on unmet medical needs, Sana aims to revolutionize treatment paradigms, positioning itself as a key player in the rapidly evolving biotechnology landscape, despite the inherent risks of drug development.

What Is the Investment Thesis for SANA?

Sana Biotechnology presents a high-risk, high-reward investment opportunity within the cell therapy space. The company's diverse pipeline targeting multiple disease areas provides potential for significant upside if clinical trials are successful. Key value drivers include the advancement of its lead candidates, SG295 and SG242, through clinical development for CD19+ cancers. Successful preclinical data for its in vivo and ex vivo platforms could also drive investor interest. However, the company faces substantial risks associated with drug development, including clinical trial failures and regulatory hurdles. Investors should closely monitor clinical trial results and cash burn rate. The company's market capitalization of $1.04B reflects the speculative nature of its pipeline.

Based on FMP financials and quantitative analysis

SANA Key Highlights

Sana Biotechnology focuses on engineered cell therapies, targeting a wide range of diseases including oncology, diabetes, and neurological disorders.

• The company's lead product candidates, SG295 and SG242, are in development for CD19+ cancers, representing a significant market opportunity.
• Sana's ex vivo and in vivo cell engineering platforms offer potential for innovative treatments across multiple therapeutic areas.
• The company's research and development efforts are focused on addressing unmet medical needs with engineered cell therapies.
• Sana Biotechnology's market capitalization is $0.93 billion, reflecting its position as a key player in the biotechnology sector.

Who Are SANA's Competitors?

SANA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SANA's Key Strengths?

Innovative cell engineering platforms.

• Diverse pipeline targeting multiple disease areas.
• Experienced management team.
• Strong intellectual property position.

What Are SANA's Weaknesses?

Early stage of development with no approved products.

• High cash burn rate.
• Dependence on clinical trial success.
• Limited manufacturing capacity.

What Could Drive SANA Stock Higher?

Clinical trial data releases for SG295 and SG242 in CD19+ cancers.

• Initiation of clinical trials for SC451 in type I diabetes mellitus.
• Advancement of preclinical programs for neurological disorders.
• Expansion of cell engineering platforms and technologies.

What Are the Key Risks for SANA?

Financial-distress signal — its Altman Z-Score of -5.43 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for key product candidates.
• Regulatory delays or rejections.
• Competition from other biotechnology companies in the cell therapy space.
• High cash burn rate and need for additional funding.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for SANA?

• Expansion in Oncology: Sana Biotechnology has a significant growth opportunity in expanding its oncology pipeline. The global oncology market is projected to reach $286.6 billion by 2028, driven by the increasing prevalence of cancer and advancements in treatment modalities. Sana's SG295 and SG242, targeting CD19+ cancers, have the potential to capture a portion of this market. Success in clinical trials and subsequent regulatory approvals could lead to substantial revenue growth for the company. The timeline for this growth is dependent on the progression of clinical trials, with potential for market entry within the next 3-5 years.
• Advancement of Diabetes Program: Sana's SC451 program for type I diabetes mellitus represents a significant growth opportunity. The global diabetes market is expected to reach $44.9 billion by 2027, driven by the rising incidence of diabetes worldwide. Sana's cell therapy approach aims to provide a functional cure for type I diabetes, potentially disrupting the existing treatment paradigm. Positive preclinical and clinical data could attract significant investment and partnerships. The timeline for this growth is dependent on clinical trial outcomes, with potential for market entry in 5-7 years.
• Development of Neurological Therapies: Sana's pipeline includes SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease, addressing a critical unmet need in neurological disorders. The global market for neurological disorders is projected to reach $15.9 billion by 2027. Successful development of these therapies could position Sana as a leader in the treatment of neurological diseases. The timeline for this growth is dependent on clinical trial progress, with potential for market entry in 7-10 years.
• Partnerships and Collaborations: Sana has the opportunity to accelerate its growth through strategic partnerships and collaborations with other biotechnology and pharmaceutical companies. Collaborations can provide access to new technologies, funding, and expertise, enabling Sana to expand its pipeline and accelerate the development of its existing programs. These partnerships can also help Sana navigate the complex regulatory landscape and commercialize its products more effectively. The timeline for this growth is ongoing, with potential for new partnerships to be announced in the near future.
• Expansion of Cell Engineering Platforms: Sana's ex vivo and in vivo cell engineering platforms provide a foundation for developing new therapies across a wide range of diseases. By expanding these platforms and developing new cell engineering technologies, Sana can create a sustainable competitive advantage and generate a pipeline of innovative product candidates. This expansion can be achieved through internal research and development, as well as through acquisitions and licensing agreements. The timeline for this growth is ongoing, with continuous investment in research and development to enhance the capabilities of its cell engineering platforms.

What Are SANA's Competitive Advantages?

• Proprietary cell engineering platforms that enable the development of novel cell therapies.
• Strong intellectual property portfolio protecting its cell engineering technologies and product candidates.
• Expertise in cell therapy development and manufacturing.
• Focus on therapeutic areas with high unmet medical needs.

What Does SANA Do?

Sana Biotechnology, Inc., founded in 2018 and headquartered in Seattle, Washington, is a biotechnology company dedicated to creating engineered cells as medicines. Formerly known as FD Therapeutics, Inc., Sana focuses on developing both ex vivo and in vivo cell engineering platforms to address a wide range of therapeutic areas with significant unmet needs. The company's diverse pipeline targets diseases including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders. Sana's product candidates include SG295 and SG242, which target CD19+ cancer cells found in non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. The company is also developing SG221 and SG239 for the treatment of multiple myeloma, and SG328 for ornithine transcarbamylase deficiency. Furthermore, Sana is advancing SG418 for sickle cell disease and beta-thalassemia, SC291, a CD19 allogeneic T cell therapy, SC255 for multiple myeloma, SC451 for type I diabetes mellitus, and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana's approach involves engineering cells to enhance their therapeutic properties, aiming to create more effective and accessible treatments for patients. The company's innovative research and development efforts are geared towards transforming the future of medicine through cell engineering.

What Products and Services Does SANA Offer?

• Develop ex vivo cell engineering platforms to modify cells outside the body for therapeutic purposes.
• Create in vivo cell engineering platforms to directly modify cells within the body.
• Focus on therapeutic areas with unmet treatment needs, including oncology, diabetes, and neurological disorders.
• Develop cell therapies for various cancers, including non-Hodgkin Lymphoma and multiple myeloma.
• Engineer cells to enhance their therapeutic properties and improve treatment outcomes.
• Advance product candidates through preclinical and clinical development stages.
• Target genetic disorders such as sickle cell disease and beta-thalassemia with cell-based therapies.

How Does SANA Make Money?

• Develop and commercialize engineered cell therapies for various diseases.
• Generate revenue through licensing agreements and partnerships with other biotechnology and pharmaceutical companies.
• Focus on research and development to create innovative cell engineering platforms and product candidates.

What Industry Does SANA Operate In?

Sana Biotechnology operates within the rapidly evolving biotechnology industry, specifically in the cell and gene therapy sector. This sector is characterized by high growth potential, driven by technological advancements and increasing demand for innovative treatments for previously incurable diseases. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, all vying for market share in areas like oncology, genetic disorders, and autoimmune diseases. The industry is subject to stringent regulatory oversight and requires significant capital investment for research and development. Sana's focus on engineered cell therapies positions it within a high-growth segment of the biotechnology market.

Who Are SANA's Key Customers?

• Patients suffering from cancers, diabetes, neurological disorders, and genetic diseases.
• Healthcare providers and hospitals that administer cell therapies.
• Pharmaceutical companies seeking to license or partner on cell therapy technologies.

How Sana Biotechnology, Inc. Is Valued

Sana Biotechnology, Inc. carries a market capitalization of $1.04B, placing it in the small-cap category. Relative to its peer group, SANA's quantitative score of 23/100 is below the peer average of 75/100.

Company Profile

Sana Biotechnology, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Steven D. Harr. SANA has traded publicly since 2021.

Key Financial Metrics

Return on assets is -49.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.38 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.5%, the inverse of the P/E and a quick read on earnings relative to price.

Sana Biotechnology, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.43 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project Sana Biotechnology, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.61.

SANA Financials

SANA Latest News

SANA Analyst Consensus

SANA MoonshotScore

What Investors Ask About Sana Biotechnology, Inc. (SANA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources